This white paper explains how early-phase clinical trials are evolving from sequential, safety-focused studies into integrated programs designed to produce faster, clearer, and more reliable development decisions. Rising costs, tighter investment scrutiny, scientific advances, and changing regulatory expectations require sponsors to generate credible evidence on dose, exposure, biological activity, safety, and early efficacy sooner. The paper highlights adaptive, hybrid, basket, and master protocol designs, supported by Bayesian analytics and real-time data review. It also stresses the importance of selecting CRO partners with strong scientific, operational, and global capabilities. Integrated delivery across clinical operations, biostatistics, pharmacology, safety, and data teams can redu

Join for free to read